A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Corvus Pharmaceuticals (NASDAQ:CRVS – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, March 18th. Analysts expect the company to announce earnings ...

BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team ...

On Thursday, Mizuho (NYSE:MFG) Securities sustained its Outperform rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) with a price target of $12.00. The firm's analyst ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Mankind Pharma, India’s fourth largest drugmaker by domestic sales, is setting its sights on anti-obesity drugs like Semaglutide, better known by brand names Ozempic and Wegovy, which goes off ...

Stäubli Robotics in collaboration with a prominent pharmaceutical company has developed a mobile robot for use in Grade A/B/C/D cleanrooms. A cross-functional team ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. Most of the major U.S. pharmaceutical companies (AbbVie, Amgen, Bristol Myers ...